Karen H. Costenbader, MD, MPH
Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Womens Hospital
Karen H. Costenbader, MD, MPH, has disclosed that she has received research funding from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.
Brad H. Rovin, MD
Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Brad H. Rovin, MD, has disclosed that he has received funds for research from Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chemocentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chugai Pharma, Corrona, EMD Serono, Genentech/Hoffman-La Roche, Janssen, Kezar Life Sciences, Lilly, Morphosys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere Therapeutics.